Can a Common Deworming Drug Hold the Key to Prostate Cancer Treatment?
"New research suggests oxibendazole, an anthelmintic drug, could significantly inhibit prostate cancer cell growth, offering a potential new avenue for treatment."
Prostate cancer is a leading health concern among men worldwide, ranking as one of the most common malignancies and a significant cause of cancer-related deaths in developed nations. Androgen deprivation therapy (ADT) has long been the standard treatment, yet its effectiveness is often undermined as the cancer develops resistance, becoming androgen-independent.
The challenge of recurrent prostate cancer has spurred a search for new therapeutic strategies. Amidst this pursuit, an unexpected contender has emerged: oxibendazole (OBZ). Known primarily as an anthelmintic drug used to combat parasitic infections, OBZ has demonstrated potential in treating various malignancies. This has prompted researchers to investigate its impact on prostate cancer cell growth.
A recent study delved into OBZ's ability to suppress the growth of prostate cancer cells, focusing on androgen-independent cell lines 22Rv1 and PC-3. The findings revealed that OBZ indeed inhibits the growth of these cells. This article breaks down the essential insights from the study, offering an accessible overview for anyone keen to understand the latest advancements in prostate cancer research.
The Continuing Burden of Prostate Cancer
The CDC's U.S. Cancer Statistics Prostate Cancer Stat Bite reports that 266,307 new prostate cancers were recorded in the United States in 2023, while 34,815 males died from the disease in 2024. The CDC provides incidence, deaths, stage distribution, and five-year relative survival data through its Prostate Cancer Statistics resources. The American Cancer Society reports that the prostate cancer death rate declined by about half from 1993 to 2022, although that decline has slowed in recent years, likely as more cancers are found at an advanced stage.
A Broad and Increasingly Complex Treatment Landscape
The National Cancer Institute lists active surveillance, surgery, radiation therapy, hormonal therapy, chemotherapy, immunotherapy, and supportive care among prostate cancer treatment options. The European Association of Urology's 2026 guidelines likewise review treatment modalities across different disease stages. Treatment selection has become more complicated as options have increased, and comparisons can be affected by stage migration and lead-time bias associated with PSA-based screening and the detection of small, clinically localized cancers.
From Early Treatments to Modern Multimodal Care
Historical accounts describe prostate cancer care as an evolving field in which scientific understanding and medical approaches changed over centuries. A review focused on the past 60 years reports substantial improvements in life-prolonging chemotherapy, androgen-suppressive treatments, diagnostic imaging, and staging. Modern treatment now includes minimally invasive surgery, brachytherapy, hormone therapy, and immunotherapy, reflecting a progression beyond the early reliance on surgery and radiation therapy.
How Oxibendazole Impacts Prostate Cancer Cell Growth
The study meticulously examined how OBZ affects prostate cancer cells in vitro, using a trypan blue exclusion assay to assess cell growth. The results indicated that OBZ significantly curtails the growth of both 22Rv1 and PC-3 cell lines. Specifically, OBZ inhibited cell growth with half-maximal inhibitory concentration values of 0.25 µM for 22Rv1 cells and 0.64 µM for PC-3 cells. These values indicate the potency of OBZ in suppressing the proliferation of these cancer cells.
- Increased miR-204 Expression: OBZ treatment led to an increase in microRNA-204 (miR-204) expression, a known tumor suppressor.
- Elevated p53 Levels: The treatment also increased the levels of p53, a protein that plays a crucial role in preventing cancer development.
- Reduced Androgen Receptor Expression: OBZ was found to reduce the expression of the androgen receptor (AR), a key factor in prostate cancer progression.
- Decreased Prostate-Specific Antigen (PSA): The study also noted a reduction in prostate-specific antigen (PSA) levels, a common marker for prostate cancer.
What Anthelmintic Repurposing Studies Suggest
Research on prostate cancer cell lines 22Rv1 and PC-3 found that oxibendazole increased expression of the tumor suppressors microRNA-204 and p53. A separate review reports that oxibendazole increased miR-24a and miR-204 in prostate cancer cells. These findings place oxibendazole within a broader research effort examining benzimidazole anthelmintic drugs as potential cancer therapeutics, although the cited evidence is preclinical.
Promising Cell Data Still Have Limits
The oxibendazole literature reports that the drug repressed the growth of PC-3 prostate cancer cells in vitro, but explicitly states that this observation requires further study in vivo. Another report notes prior evidence of oxibendazole safety in ruminants, laboratory animals, and humans at concentrations up to 30 mg/kg, while presenting that evidence as support for further study rather than proof of prostate cancer treatment efficacy. Contemporary prostate cancer care also already includes active surveillance, novel hormone therapies, immunotherapy, precision medicine, and combination approaches, so any repurposed drug would need to be evaluated against established and emerging strategies.
The Promising Future of Oxibendazole in Cancer Therapy
The findings of this study illuminate the potential of oxibendazole as a therapeutic agent for recurrent prostate cancer. By targeting androgen-independent pathways and enhancing the expression of tumor-suppressing factors, OBZ offers a multi-faceted approach to combating cancer cell growth. While further research is essential to fully understand its effects and optimize its use, oxibendazole represents a promising new direction in the ongoing fight against prostate cancer. It is important to note that this research is still in its early stages, and OBZ is not yet approved for use in prostate cancer treatment.
Treatment Choices Require Comparative Evidence
A systematic review and meta-analysis describes comparative effectiveness analysis as essential because prostate cancer has multiple alternative treatment strategies. Its focus is on outcomes that matter to patients with newly diagnosed localized disease. For metastatic castration-sensitive prostate cancer, expert commentary reports that adding androgen deprivation therapy to newer androgen receptor pathway inhibitors has created a treatment landscape in which there is no guidance identifying the best treatment after progression to metastatic castration-resistant disease.
Toward Biomarker-Guided Care
Recent work identifies androgen receptor signaling, biomarkers, molecular-targeted therapy, personalized medicine, and treatment resistance as central themes in future prostate cancer research. Another recent overview describes a changing care landscape built on established approaches such as PSA testing, digital rectal examination, biopsy, radiation therapy, and radical prostatectomy. It also emphasizes that these approaches, while life-saving, are not without limitations, reinforcing the need for improved diagnostic and treatment strategies.
Progress With Persistent Uncertainty
A 2026 review describes improvements in prostate cancer management over the past two decades, driven by better detection of metastatic disease, biomarker characterization, and treatment. Its scope includes high-risk biochemical recurrence, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. A separate expert review highlights persistent uncertainties in biomarker-guided assessment, imaging, and systemic therapy, indicating that progress has not eliminated important evidence gaps.
What Happens Beyond Clinical Trials
Real-world data on managing metastatic castration-resistant prostate cancer with newer therapies remain sparse, according to a study of patients in Greece who began first-line systemic treatment with chemotherapy or novel hormonal agents. That study aimed to describe therapeutic sequencing in routine care. Other real-world research has examined treatment patterns and outcomes among men with localized or locally advanced disease after radiotherapy or radical prostatectomy, using Optum claims and electronic health records collected from January 2010 through December 2021.